Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Akoya Biosciences, Inc. AKYA
$5.69
-$0.5 (-8.81%)
На 18:04, 12 мая 2023
+198.77%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
259583324.00000000
-
week52high
16.57
-
week52low
6.22
-
Revenue
74859000
-
P/E TTM
-4
-
Beta
0.91912000
-
EPS
-1.90000000
-
Last Dividend
0.00000000
-
Next Earnings Date
08 мая 2023 г. в 20:00
Описание компании
Akoya Biosciences, Inc., a life sciences technology company, provides spatial biology solutions focused on transforming discovery and clinical research in North America, the Asia Pacific, Europe, the Middle East, and Africa. The company offers PhenoCycler instrument, a compact bench-top fluidics system that integrates with a companion microscope to automate image acquisition; and PhenoImager platform that enables researchers to visualize, analyze, quantify, and phenotype cells in situ, in fresh frozen or FFPE tissue sections, and tissue microarrays utilizing an automated and high-throughput workflow. It also provides PhenoCycler and PhenoImager reagents; and biopharma services. In addition, the company offers Proxima, a cloud-based platform to store, analyze, and share spatial data; inForm Tissue, an automated image analysis software package for accurately visualizing and quantifying biomarkers in tissue sections; Phenoptr, which provides functions that consolidate and analyze output tables created by inForm software; and phenoptrReports, a software that generates shareable reports and visualizations based on the phenoptr output in an intuitive front-end GUI. The company was incorporated in 2015 and is headquartered in Marlborough, Massachusetts.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Piper Sandler | Overweight | Overweight | 18 авг 2022 г. |
| BTIG | Buy | 22 июн 2022 г. | |
| Piper Sandler | Overweight | Overweight | 16 мая 2022 г. |
| Morgan Stanley | Overweight | Overweight | 09 мая 2022 г. |
| Piper Sandler | Overweight | Overweight | 18 мар 2022 г. |
| Stephens & Co. | Overweight | 06 окт 2022 г. | |
| Capital One | Overweight | 03 ноя 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| DRISCOLL JOSEPH | D | 110958 | 250000 | 22 дек 2022 г. |
| DRISCOLL JOSEPH | A | 262500 | 250000 | 22 дек 2022 г. |
| DRISCOLL JOSEPH | D | 108712 | 14574 | 14 дек 2022 г. |
| DRISCOLL JOSEPH | D | 123466 | 10039 | 14 дек 2022 г. |
| DRISCOLL JOSEPH | D | 12500 | 14574 | 14 дек 2022 г. |
| DRISCOLL JOSEPH | A | 27074 | 14574 | 14 дек 2022 г. |
| DRISCOLL JOSEPH | A | 22539 | 10039 | 14 дек 2022 г. |
| SCHNETTLER THOMAS P | D | 2742721 | 71050 | 13 дек 2022 г. |
| McKelligon Brian | D | 338129 | 5000 | 06 дек 2022 г. |
| McKelligon Brian | D | 80000 | 5000 | 06 дек 2022 г. |
Новостная лента
Akoya to Report Fourth Quarter and Full Year 2022 Financial Results on March 6th, 2023 and Participate at Two Upcoming Investor Conferences
GlobeNewsWire
06 февр 2023 г. в 08:05
MARLBOROUGH, Mass., Feb. 06, 2023 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced that it will release financial results for the fourth quarter and full year of 2022 after the market close on Monday, March 6th, 2023. Company management will host a conference call to discuss financial results at 5:00 p.m. ET.
Akoya Biosciences to Present First-of-its-Kind Spatial Multiomics Dataset at 2023 AGBT General Meeting
GlobeNewsWire
01 февр 2023 г. в 08:00
Simultaneous detection of proteins and RNA markers across 23 different tissue samples demonstrate robust and scalable capabilities of company's multiomics solution Simultaneous detection of proteins and RNA markers across 23 different tissue samples demonstrate robust and scalable capabilities of company's multiomics solution
Akoya Bioscience: Something Special For Investing In A Spatial Bioscience Company
Seeking Alpha
26 янв 2023 г. в 15:13
I will provide readers the basics of what a spatial biotech offers. A key catalyst should drive the future of this bioscience company.
Akoya Biosciences, Inc. (AKYA) Q3 2022 Earnings Call Transcript
Seeking Alpha
07 ноя 2022 г. в 20:04
Akoya Biosciences, Inc. (NASDAQ:AKYA ) Q3 2022 Earnings Conference Call November 7, 2022 5:00 PM ET Company Participants Priyam Shah - Senior Director, Investor Relations Brian McKelligon - Chief Executive Officer Joseph Driscoll - Chief Financial Officer Conference Call Participants Mason Carrico - Stephens Mark Massaro - BTIG Neil Vibhakar - Morgan Stanley Operator Good day and thank you for standing by. Welcome to the Akoya Biosciences Third Quarter 2022 Earnings Conference Call.
Akoya Biosciences (AKYA) Reports Q3 Loss, Tops Revenue Estimates
Zacks Investment Research
07 ноя 2022 г. в 18:56
Akoya (AKYA) delivered earnings and revenue surprises of -17.50% and 5.89%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?